News
INVO Bioscience to Participate in Roundtable Discussion at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
SARASOTA, Fla., March 22, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, announced...
New Birmingham INVO Center Offers Families an Affordable Advanced Fertility Treatment Solution to Help Combat Rising Costs
SARASOTA, Fla., March 10, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), developers of the INVOcell®, an advanced fertility treatment technology which is currently available through a number of channels, including its new joint-venture owned INVO...
INVO to Launch Additional INVO Center in Tampa, Florida
Tampa INVO Center to focus on advanced fertility care utilizing INVOcell®SARASOTA, Fla. and TAMPA, Fla., Feb. 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment...
INVO Bioscience Eyes +20 U.S. Cities To Expand Rollout Of Advanced Infertility Treatment ‘INVO Centers’
SAN FRANCISCO, CA / ACCESSWIRE / February 9, 2022 / Today, the global fertility market is a multi-billion industry, yet remains severely underserved, with estimates suggesting more than 90% of couples in need of infertility treatment going without care. INVO...
INVO Bioscience Expands U.S. Commercialization Efforts
Focused on addressing underserved patients within the fertility marketplaceSARASOTA, Fla., Feb. 3, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) ("Company") ("INVO"), a commercial-stage fertility company focused on expanding access to advanced treatment...
INVO Bioscience Enters into Agreement with Ovoclinic in Spain to Expand INVOcell Commercialization
Agreement follows initial utilization of INVOcell by Ovoclinic phyisicians in early 2021, resulting in successful patient experiences and outcomesOvoclinic will expand use of INVOcell in all four of their clinics and become the Center of Excellence and Training Site...
INVO Bioscience to Participate in the Lytham Partners Winter 2021 Investor Conference
SARASOTA, Fla., Dec. 10, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, announced today that it will be participating in the Lytham Partners...
INVO Bioscience Obtains Regulatory Approval to Commercialize INVOcell In Thailand
INVO's distribution partner, IVF Envimed Company Ltd., set to begin commercialization of the INVOcell system within Thailand.SARASOTA, Fla., Dec. 1, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the...
INVO Bioscience Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update
Company to Host Conference Call Today at 4:30pm ET (Details Below)SARASOTA, Fla., Nov. 15, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a medical device company focused on creating alternative treatments for patients diagnosed...
INVO Bioscience to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ETSARASOTA, Fla., Nov. 9, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Culture...